fasting and tirzepatide GLP-1 receptor agonists can be continued before anesthesia with extended Weight loss drugs GLP-1 Pathway Support Bundles:3 Bottles

fasting and tirzepatide GLP-1 receptor agonists can be continued before anesthesia with extended Weight loss drugs GLP-1 Pathway Support Bundles:3 Bottles

Weight loss drugs

Protocol 2: the balanced approach (most common) Goal: Reduce side effects while reaching therapeutic doses in a reasonable timeframe Best for: First-time users, people who want a smoother experience than standard titration, those working with compounded formulations Complete schedule: Weeks 1-2: 0.25 mg weekly Weeks 3-4: 0.5 mg weekly Week 5: 1.0 mg weekly Weeks 6-7: 1.5 mg weekly Week 8-9: 2.0 mg weekly Weeks 10-13: 2.5 mg weekly Weeks 14-17: 5.0 mg weekly Time to therapeutic dose: 13-17 weeks Expected results: Mild GI effects at most transitions, noticeable appetite suppression by weeks 6-8, meaningful weight loss beginning around weeks 10-13 This is the protocol most practitioners recommend when patients specifically request microdosing

GLP-1 Pathway Support

Bundles:3 Bottles

Lower Maintenance Doses An emerging strategy is to taper to a lower maintenance dose after maximum weight loss is achieved, aiming to prevent regain while reducing drug exposure, side effects, and cost